Dr. Cheryl K. McDonald, MD

Dr. McDonald practices at Texas Centers for Infectious Disease Associates PA in Fort Worth, Texas.

Dr. McDonald's NPI, 1013982511, was assigned on February 20, 2006. Dr. McDonald graduated from UT Southwestern Medical Center in 1989. Dr. McDonald holds Texas license H7634.

Dr. McDonald's primary practice is Texas Centers for Infectious Disease Associates PA, at 1025 College Ave, Fort Worth, TX 76104 in Tarrant County. The practice phone is (817) 810-9811.

Dr. McDonald's primary practice is Texas Centers for Infectious Disease Associates PA in Fort Worth, Texas. Dr. McDonald is also affiliated with Texas Health Fort Worth. The medical group on file is Texas Centers for Infectious Disease Associates. Dmand AI also links Dr. McDonald to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McDonald practices, 6 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. McDonald's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. McDonald is board certified in infectious disease by the American Board of Internal Medicine. Dmand AI has Dr. McDonald's licenses on file in 3 states: Texas, Colorado and Alabama.

Dmand AI lists acute skin infection, facial skin infection, hiv/aids, immune deficiency disease, joint or bone infection, pneumonia, urinary tract infection and UTI among the conditions Dr. McDonald treats.

CMS data shows 24,549 Medicare services from Dr. McDonald across 16 procedure codes in 2024, for 721 Medicare patients. Medicare paid $1,005,743 for them.

CMS counts 721 Medicare patients who saw Dr. McDonald in 2024. The largest group is 65 to 74, with 292 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. McDonald's median patient age at 66, with 47% women.

In 2024, Dr. McDonald wrote 3,909 Medicare Part D claims for 399 patients. 62% of them were for generic drugs. CMS names the drug for 3,594 of them, across 79 drugs with 11 or more claims each, at $6,419,374 in total drug cost. In 2023, CMS named 3,137 claims across 77 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. McDonald for performance year 2024, reported as part of a group. Dr. McDonald accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 14 papers to Dr. McDonald, published from 2012 to 2018. 2018 was the busiest year, with 2. The most frequent topics are HIV Infections, Anti-HIV Agents and Emtricitabine. Dr. McDonald has published most often in J Acquir Immune Defic Syndr. Dr. McDonald's most frequent co-authors are Moupali Das, MD, Moti N. Ramgopal, MD and Joseph J. Eron, MD.

Dmand AI links Dr. McDonald to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Clostridium Infections, Paramyxoviridae Infections and Gram-Positive Bacterial Infections.

CMS Open Payments shows 924 general payments to Dr. McDonald from 35 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 72% of the total. Gilead Sciences, Inc. paid the most, $156,112. It also lists 23 research payments totaling $2,273 from 2017 to 2019.

Dmand AI lists 3 awards for Dr. McDonald, most recently CMS Stage 1 EHR in 2013.

Dr. McDonald graduated from UT Southwestern Medical Center in 1989. Dr. McDonald is a member of ACP.

Dr. McDonald is in network with 23 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.